

---

# Worldwide Dissemination of the *bla*<sub>OXA-23</sub> Carbapenemase Gene of *Acinetobacter baumannii*<sup>1</sup>

Pauline D. Mugnier, Laurent Poirel, Thierry Naas, and Patrice Nordmann

To assess dissemination of OXA-23–producing strains of *Acinetobacter baumannii*, we obtained 20 carbapenem-resistant, OXA-23–producing isolates from different regions. Their clonal relationship was assessed by pulsed-field gel electrophoresis and multilocus sequence typing. We identified 8 sequence types, including 4 novel types. All except 2 strains belonged to 2 main European clonal lineages. The *bla*<sub>OXA-23</sub> gene was either located on the chromosome or on plasmids and associated with 4 genetic structures.

*Acinetobacter baumannii* is a gram-negative organism that is increasingly recognized as a major pathogen causing nosocomial infections, including bacteremia and ventilator-associated pneumonia, particularly in patients admitted to intensive care units (1). Several studies have shown the geographically widespread occurrence of multidrug-resistant *A. baumannii* strains, which suggested a clonal relatedness of these strains. Three international *A. baumannii* clones associated with multidrug resistance (European clones I, II, and III) have been reported (2).

Increasing resistance to carbapenems has been observed worldwide in the past decade, frequently mediated by production of class D  $\beta$ -lactamases with carbapenemase activity. Three acquired class D  $\beta$ -lactamases with carbapenemase gene clusters have been described in *A. baumannii*, which correspond to *bla*<sub>OXA-23</sub>-like, *bla*<sub>OXA-40</sub>-like, and *bla*<sub>OXA-58</sub>-like genes (3). The *bla*<sub>OXA-23</sub> gene, first characterized in Scotland (4), has been increasingly reported worldwide. *A. radioresistens* was recently identified as the progenitor of the *bla*<sub>OXA-23</sub>-like genes (5). Clonal outbreaks of

carbapenem-resistant and OXA-23–producing *A. baumannii* have been reported in many countries, such as Bulgaria (6), People's Republic of China (7), Brazil (8), Iraq (9), Afghanistan (9), and French Polynesia (10).

Genetic acquisition of the *bla*<sub>OXA-23</sub> gene was investigated and transposons Tn2006, Tn2007, and Tn2008 were identified as genetic structures harboring this gene (10–12). In Tn2006, the *bla*<sub>OXA-23</sub> gene is flanked by 2 copies of the insertion sequence IS*Aba1*, which are located in opposite orientations (Figure 1). The functionality of Tn2006 has been recently demonstrated (13). Tn2008 is similar to Tn2006 but lacks the second copy of IS*Aba1* and the *bla*<sub>OXA-23</sub> gene is associated with 1 copy of IS*Aba4* (which differs from IS*Aba1*) in Tn2007 (Figure 1) (11). As reported for strains from United Arab Emirates and Bahrain, the *bla*<sub>OXA-23</sub> gene can be associated with only 1 copy of IS*Aba1* (14,15). We studied the clonal relationship and genomic environment of sequences surrounding the *bla*<sub>OXA-23</sub> gene among a collection of OXA-23–producing isolates from 15 countries.

## Materials and Methods

### Bacterial Strains and Susceptibility Testing

Twenty OXA-23–producing *A. baumannii* clinical isolates were obtained from 15 countries. These isolates had been obtained from patients hospitalized in intensive care units from December 2003 through March 2008. Isolates were obtained from tracheal aspirates (n = 3), bile (n = 1), urine (n = 4), wounds (n = 1), respiratory tract (n = 1), blood (n = 4), and sputum (n = 1). The isolates were initially chosen after preliminary pulsed-field gel electrophoresis (PFGE)–based typing had identified 13 pulsotypes. Isolates

---

Author affiliations: Institut National de la Santé et de la Recherche Médicale Unité 914, Paris, France; and Université Paris Sud, Bicêtre, France

DOI: 10.3201/eid1601.090852

---

<sup>1</sup>This work was presented in part at the 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16–19, 2009.

were obtained from France (n = 4), Vietnam (n = 1), New Caledonia (n = 1), Thailand (n = 1), Australia (n = 1), Tahiti (n = 1), Reunion (n = 2), South Africa (n = 1), United Arab Emirates (n = 2), Libya, (n = 1), Bahrain (n = 1), Egypt (n = 1), Belgium (n = 1), Algeria (n = 1), and Brazil (n = 1).

Presence of the *bla*<sub>OXA-23</sub> gene was screened by PCR by using specific primers (OXA-23-A 5'-GGA ATTCCATGAATAAATATTTTACTTGC-3' and OXA-23-B 5'-CGGGATCCCGTTAAATAATATTCAGGTC-3') and additional sequencing (ABI 3100 sequencer; Applied Biosystems, Foster City, CA, USA). Susceptibility patterns to  $\beta$ -lactam antimicrobial drugs were determined by using a standard disk diffusion method according to published standards (16) and Etest strips (AB Biodisk, Solna, Sweden). Isolates were identified by using 16S rRNA gene sequencing (17).

### Clonal Relationships

Isolates were typed by using *Apa*I macrorestriction analysis and PFGE according to the manufacturer's recommendations (Bio-Rad, Marnes-la-Coquette, France). Bacteria were grown in a medium appropriate for the strain until an optical density of 0.8 to 1 at 600 nm was reached. One milliliter of cells was centrifuged, washed, and resuspended in 10 mmol/L Tris, pH 7.2, 20 mmol/L NaCl, 50 mmol/L EDTA. Immediately after resuspension, an equal volume of 2% low melting point InCert agarose (Bio-Rad) was added. Solid agarose plugs were lysed at 37°C for 2 h in 1 mL of lysis buffer (10 mmol/L Tris, pH 7.2, 50 mmol/L NaCl, 0.5% sodium laurylsarcosine, 0.2% sodium deoxycholate) supplemented with 20 mg/L of lysozyme. The plugs were then incubated at 55°C for 16 h with proteinase K buffer (100 mmol/L EDTA, pH 8, 0.2% sodium deoxycholate, 1% sodium laurylsarcosine) supplemented with 20 mg/L of proteinase K. Plugs were washed with Tris-EDTA buffer containing 1 mmol/L phenylmethylsulfonyl fluoride

(Sigma, St. Louis, MO, USA) and 3 $\times$  with Tris-EDTA buffer at room temperature.

Whole-cell DNA of *A. baumannii* isolates was digested with *Apa*I overnight at room temperature (New England Biolabs, St. Quentin-en-Yvelines, France). Electrophoresis was performed on a 1% agarose gel with 0.5 $\times$  Tris-borate-EDTA buffer by using a CHEF DRII apparatus (Bio-Rad). Samples were subjected to electrophoresis at 14°C, 6 volts/cm, and a switch angle with 1 linear switch ramp of 3–8 s for 10.5 h, and then for 12–20 s for 10.5 h.

Identification of PCR-based sequence groups was conducted by using 2 multiplex PCR assays designed to selectively amplify group 1 or group 2 alleles of the gene encoding outer-membrane protein A (*ompA*), the gene encoding part of a pilus assembly system required for biofilm formation (*csuE*), and the gene encoding the intrinsic carbapenemase gene of *A. baumannii* (*bla*<sub>OXA-51</sub>) (18). Clonal relationships were established by multilocus sequence typing (MLST) by using 7 standard housekeeping loci (citrate synthase [*gltA*], gyrase B [*gyrB*], glucose dehydrogenase B [*gdhB*], recombination A [*recA*], chaperone 60 [*cpn60*], glucose-6-phosphate isomerase [*gpi*], and RNA polymerase [*rpoD*]) as described (18). Sequencing of internal fragments was performed by using BigDye fluorescent terminators and primers described (19). Sequences were compared with the *A. baumannii* database at the MLST Website (<http://mlst.zoo.ox.ac.uk>). To supplement epidemiologic results, we performed a second MLST typing using the scheme developed by Nemeč et al. (20). Sequences of the 7 housekeeping genes were analyzed by using an *A. baumannii* database ([www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html](http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html)).

### Southern Blot Analysis and Location of *bla*<sub>OXA-23</sub> Gene

Southern blot analysis was performed by using total genomic DNA digested with *Eco*RI, separated by electro-




Figure 1. Genetic structures associated with the *bla*<sub>OXA-23</sub> gene of *Acinetobacter baumannii*. A) Tn2006 from isolates 240, 512, 810, 859, 883 and AUS (ST22/ST2). B) Tn2008 from isolate 614. C) Tn2007 from isolates Ab14, BEL, and DOS. D) ISAbal from isolates AS3, 1190, 861, and 877. Boundaries of Tn2006, Tn2007, and Tn2008 are indicated with the target site duplication likely generated by transposition events underlined. The 7-bp difference in the site of insertion of ISAbal for isolate 614 is double-underlined. The open reading frame 1 (*orf1*), *orf2*, and *orf3* genes of unknown function is indicated. *tnpA*, gene encoding a putative transposase; *ATPase*, gene encoding the putative AAA ATPase; *DEAD*, gene encoding the putative DEAD (Asp-Glu-Ala-Asp) helicase; *DNAmethyl*, DNA methylase.

phoresis on 0.8% agarose gels, transferred onto Hybond N+ membranes, and hybridized with enhanced chemiluminescence labeled probes overnight at 42°C. The membranes were developed according to the manufacturer's instructions (GE Healthcare, Saclay, France). Chromosomal or plasmid locations of the  $\beta$ -lactamase gene were assessed by hybridization of *I-CeuI*-digested genomic DNA with *bla*<sub>OXA-23</sub> and 16S rDNA probes and electrophoresis (20–120 s for 9 h and 60–100 s for 11 h at 14°C and 5 V/cm<sup>2</sup>) (21). DNA was transferred from an agarose gel to a nylon membrane by capillary transfer. Hybridization, labeling, and detection were conducted as described above. Mating-out assays were performed by using isolates that had plasmid-borne *bla*<sub>OXA-23</sub> as donors and rifampin-resistant *A. baumannii* BM4547 as recipients as described (22). Transconjugants were selected on trypticase soy agar plates containing ticarcillin (50 mg/L) and rifampin (50 mg/L).

### Cloning Experiments

To identify entire transposon structures containing the *bla*<sub>OXA-23</sub> gene in different isolates and determine their location in the target DNA, a cloning procedure was used. Some data had been reported for 6 of 20 isolates (11). Total DNA was digested with either *SacI* or *SallI*, ligated into the *SacI* or *SallI* sites of plasmid pBK-CMV (kanamycin-resistant cloning vector), and the recombinant plasmids were transformed into *Escherichia coli* TOP10, as described (14). Recombinant plasmids were selected on trypticase soy agar plates containing amoxicillin (50 mg/L) and kanamycin (30 mg/L). Cloned DNA fragments of several recombinant plasmids were sequenced on both strands by primer walking as described (11).

## Results

### Clonal Relatedness of the Isolates

Twenty carbapenem-resistant *A. baumannii* isolates were obtained from 15 countries (Table). All isolates were highly resistant to ticarcillin (MIC >256 mg/L) and showed a high level of resistance to ceftazidime (MIC >256 mg/L), except isolates Ab14 (MIC 4 mg/L) 861 and DOS (MIC 8 mg/L). All isolates were resistant to imipenem and meropenem (MIC  $\geq$ 16 mg/L) (Table).

Multiplex PCR for identification of sequence groups showed 10 isolates that belonged to group 1 according to Turton et al. (18), eight that belonged to group 2, and 2 isolates that did not belong to groups 1 or 2. The 10 isolates that belonged to group 1 and corresponded to European clone II (18) were classified into 2 sequence types (STs), ST22 and ST53, according to MLST analysis (18). ST22 (1–3–3–2–2–7–3) was the most frequent type identified. Nine isolates were identified: 2 from France and 1 each from Vietnam, New Caledonia, Thailand, Australia, Ta-

hiti, Reunion, and South Africa. A single European clone II isolate was classified as ST53 (1–3–3–2–2,3–3), a single-locus variant of ST22. Among 10 other isolates, 8 belonged to group 2 (corresponding to European clone I). Four STs were identified: ST25 (10–12–4–11–1–9–5) (Libya, United Arab Emirates, and Bahrain), ST44 (10–12–4–11–4–9–5) (United Arab Emirates and Algeria), and 2 new STs, 1 for isolates from Reunion and Egypt (10–12–4–11–4–16–5) and another related ST identified in the single isolate from Belgium (10–12–4–11–4,4–5). These 4 STs differ by 1 locus. The 2 most recent isolates from France and Brazil did not belong to European clones I or II and corresponded to 2 STs (1–22–3–11–1–9–7 and 12–18–12–1–15–9–19, respectively) (Table). Although 8 STs were identified in this collection, 9 pulsotypes were characterized by PFGE according to the criteria of Tenover et al. (23) (Figure 2).

According to MLST analysis developed by Nemeček et al. (20), all isolates that belonged to European clone II had the same sequence type (ST2) (2,2–2,2–2,2–2), including isolate 585, which had a distinct but related ST in the first analysis. Among isolates that belonged to European clone I, two sequence types were determined: ST20 (3–1–1,1–5–1–1) (Libya, United Arab Emirates, Bahrain) and ST1 (1,1–1,1–5–1–1) (United Arab Emirates, Reunion, Egypt, Belgium, Algeria). Isolates 910 (Reunion), 861 (Egypt), and BEL (Belgium) were included in ST1. These isolates had a distinct ST according to methods of Bartual et al. (19). The 2 most recent isolates were classified into 2 STs, a new ST (3–2–2,2–5–4–8) for isolate DOS (France) and ST15 (6,6–8–2–3–5–4) for isolate 877 (Brazil) (Table).

### Location and Transferability of the *bla*<sub>OXA-23</sub> Gene

Location of the *bla*<sub>OXA-23</sub> gene was evaluated by using the *I-CeuI* method. Eleven isolates had the *bla*<sub>OXA-23</sub> gene on the chromosome, with a hybridization signal for an  $\approx$ 40-kb band for isolate AS1 and an  $\approx$ 200-kb band for 10 isolates (Table). Nine isolates carried the *bla*<sub>OXA-23</sub> gene on a plasmid and 1 isolate had 2 copies of the *bla*<sub>OXA-23</sub> gene, 1 on the chromosome and 1 on a 7-kb plasmid (Table).

To examine the copy number of the *bla*<sub>OXA-23</sub> gene in different *A. baumannii* genomes, we performed Southern blot hybridization on *EcoRI*-digested DNA fragments using a 589-bp DNA probe specific for the *bla*<sub>OXA-23</sub> gene. Sixteen isolates showed only 1 copy of the *bla*<sub>OXA-23</sub> gene. Isolates BEL, Ab14, and DOS had 2 copies of the *bla*<sub>OXA-23</sub> gene on different plasmids, and Ab13 had 1 copy on the chromosome and 1 copy on a plasmid according to results of the *I-CeuI* technique.

Mating-out assays were performed by using the 10 plasmid-positive strains as donor strains and rifampin-resistant *A. baumannii* BM4547 as the recipient strain. Five transconjugants were obtained; all had a 130-kb plasmid that did not provide additional antimicrobial drug resistance

Table. Characteristics of 20 *bla*<sub>OXA-23</sub>-positive *Acinetobacter baumannii* clinical isolates\*

Isolate	Origin	Date of isolation	Specimen	EC	ST†	Copy no. of <i>bla</i> <sub>OXA-23</sub>	Genetic location and size, kb	Genetic structure	MIC, µg/mL		
									CAZ	IPM	MEM
240	France	2003 Dec	Tracheal aspirate	II	22/2	1	Chromosome, ≈200‡	Tn2006	128	>32	>32
512	Tahiti	2004 Mar	Tracheal aspirate	II	22/2	1	Chromosome, ≈200‡	Tn2006	64	>32	>32
761	Vietnam	2005 May	Bile	II	22/2	1	Chromosome, ≈200‡	Tn2006	64	>32	>32
810	New Caledonia	2004 Jun	Blood	II	22/2	1	Chromosome, ≈200‡	Tn2006	96	>32	>32
863	Thailand	2006 Jun	Urine	II	22/2	1	Chromosome, ≈200‡	Tn2006	256	>32	>32
883	Reunion	2006 Jun	Unknown	II	22/2	1	Chromosome, ≈200‡	Tn2006	128	>32	>32
Ab13	France	2004 Jun	Urine	II	22/2	2	Chromosome, ≈200,‡ and plasmid, 70	Tn2006	128	>32	>32
AUS	Australia	2004 Oct	Urine	II	22/2	1	Chromosome, ≈200‡	Tn2006	96	>32	>32
859	South Africa	2006 Jan	Urine	II	22/2	1	Chromosome, ≈200‡	Tn2006	128	>32	>32
585	France	2004 Jul	Tracheal aspirate	II	53/2	1	Chromosome, ≈200‡	Tn2006	128	>32	>32
614	Libya	2004 Oct	Unknown	I	25/20	1	Plasmid, 130	Tn2008	256	>32	16
AS3	UAE†	2006 Oct	Blood	I	25/20	1	Plasmid, 130	ISAba1	256	>32	>32
1190	Bahrain	2008 Mar	Blood	I	25/20	1	Plasmid, 130	ISAba1	256	>32	>32
AS1	UAE	2006 Jul	Blood	I	44/1	1	Chromosome, ≈40‡	Tn2006	256	>32	>32
Ab14	Algeria	2004 Dec	Unknown	I	44/1	2	Plasmid, 25, and plasmid, >150	Tn2007	4	16	>32
910	Reunion	2006 Oct	Unknown	I	New1/1	1	Plasmid, 130	Tn2006	256	16	16
861	Egypt	2005 Nov	Sputum	I	New1/ 1	1	Plasmid, 130	ISAba1	8	32	32
BEL	Belgium	2007 Jul	Respiratory tract	I	New2/ 1	2	Plasmid, 25, and plasmid, >150	Tn2007	256	>32	>32
DOS	France	2004 May	Unknown	–	New3/ New	2	Plasmid, 25, and plasmid, >150	Tn2007	8	>32	>32
877	Brazil	2006 Jul	Wound	–	New4/15	1	Plasmid, 130	ISAba1	96	>32	>32

\*EC, European clone; ST, sequence type; UAE, United Arab Emirates; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem. The MIC for ticarcillin was >256 µg/mL for all 20 isolates.

†ST determined by Bartual et al. (19) compared with ST determined by Nemeč et al. (20).

‡Size of chromosome band carrying the *bla*<sub>OXA-23</sub> gene, as determined by using the I-Ceul technique.

to the *A. baumannii* recipient strain, except in 1 case (co-resistance to kanamycin and amikacin on a *bla*<sub>OXA-23</sub>-carrying plasmid that originated from isolate 1190). Plasmids carrying the *bla*<sub>OXA-23</sub> gene in isolates Ab14, DOS, BEL, and 877 were not self-transferable (Table) (24).

#### Variability of Genetic Structures Flanking the *bla*<sub>OXA-23</sub> Gene

The 10 isolates that belonged to European clone II had a *bla*<sub>OXA-23</sub> gene that was part of Tn2006. The 9-bp direct repeat (DR) that corresponded to duplication of the Tn2006 target site, which was consistent with a transposition event, was identified in the 9 ST22/ST2 isolates. Tn2006 was inserted in different locations on the chromosomes of those isolates (Table). For isolates 240, 512, 810, 859, 883, and Aus, the insertion occurred between 2 genes encoding hypothetical proteins (DR: GTCATTTAA) (Figure 1). In iso-

late 761, transposon Tn2006 was located between a gene encoding a hypothetical protein and a gene encoding an isoleucyl tRNA synthase (DR: ATTCGCGGG). In isolate 863, Tn2006 was identified between a gene encoding a cytochrome D terminale oxidase and a putative transposase (DR: ATAATTATT). In isolate 585, Tn2006 was located between a gene encoding a hypothetical protein and a *sull* gene (DR: ATTCGCGGG). The plasmid-borne *bla*<sub>OXA-23</sub> gene identified in isolate Ab13 was also part of Tn2006 but was inserted into the *sul* gene that encoded a putative sulfonamide resistance determinant (DR: ATTCGCGGG).

Isolates that belonged to European clone I had diverse genetic structures at the origin of *bla*<sub>OXA-23</sub> acquisition. Two isolates had transposon Tn2006: one on the chromosome (AS1) and 1 on a plasmid (910). Transposon Tn2007 was identified in 3 isolates; it was specific for the same open reading frame in 2 isolates (BEL and Ab14) (Figure 2).




Figure 2. Pulsed-field electrophoresis (PFGE) profiles of *Apal*-digested genomic DNA from strains of *Acinetobacter baumannii*. PFGE types, European clone types, and multilocus sequence typing (MLST) results are shown. \*ST, sequence type determined by Bartual et al. (19) compared with ST determined by Nemeč et al. (20). Lane M, molecular size markers (48.5 kb).

Only 1 copy of *ISAbal* was identified upstream of the *bla*<sub>OXA-23</sub> gene in isolates AS3, 1190, 861, and 877. Transposon Tn2008 was identified only in isolate 614 (Figure 1). Sequences of these specific genetic structures have been deposited in Genbank (accession nos. EF127491, EF059914, GQ861438, and GQ861439).

## Discussion

This study was conducted to define which features may explain the worldwide dissemination of the *bla*<sub>OXA-23</sub> gene in *A. baumannii*. Isolates were from the Middle East, Europe, and Asia; there were no isolates from North America. Except for 2 isolates, the isolates investigated in this study belonged to European clones I or II. Clustering of *A. baumannii* isolates was determined by MLST and PFGE; our collection was composed of 13 PFGE types corresponding to 9 STs. Eight STs were identified among the OXA-23-producing *A. baumannii*; the most common STs were ST22/ST2 found in France ( $n = 2$ ), Vietnam, New Caledonia, Thailand, Australia, Reunion, South Africa, and Tahiti. Spread of *bla*<sub>OXA-23</sub>-positive *A. baumannii* isolates that belong to clone ST22 has been demonstrated in South Korea (25). Analysis of the target site of *bla*<sub>OXA-23</sub> acquisition showed that in the same clone, such as ST22, acquisition of the Tn2006 composite transposon had occurred at different positions in the *A. baumannii* genome, which suggested that Tn2006-mediated acquisition of *bla*<sub>OXA-23</sub> may occur as independent events, or that Tn2006 is a structure that is mobile in a given genome. A single clone could have

different genetic structures at the origin of the *bla*<sub>OXA-23</sub> acquisition.

We showed that the *bla*<sub>OXA-23</sub> gene associated with Tn2006 could be located on the chromosome or a plasmid. This result agrees with our recent findings, which showed that Tn2006 is capable of transposition (13). We have also observed that 5 isolates with different sequence types (ST-New1, ST25) harbored a similar 130-kb plasmid. The same strains with the same genetic structure were identified in 8 countries in different parts of the world.

In conclusion, the current worldwide dissemination of the *bla*<sub>OXA-23</sub> gene is driven by  $\geq 7$  MLST types associated with different genetic structures and plasmids. We have identified complex and dynamic spreading of *bla*<sub>OXA-23</sub> that will be difficult to control because this spread is not associated with a single entity.

## Acknowledgment

We thank Rémy Bonnin for technical assistance.

This study was supported by a grant from the Ministère de la Recherche, Université Paris XI, Paris, France; grants from the European Community (DRESP2, LSHM-CT-2005-01705, and TROCAR HEALTH-F3-2008-223031); and the Institut National de la Santé et de la Recherche Médicale, France.

Ms Mugnier is a doctoral student at Hôpital de Bicêtre, Institut National et de la Santé et de la Recherche Médicale, Unité, South-Paris Medical School, University Paris-XI in Le Kremlin-Bicêtre, France. Her research interests are genetic plasticity and drug-resistance mechanisms in *A. baumannii*.

## References

- Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2007;51:3471–84. DOI: 10.1128/AAC.01464-06
- Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev*. 2008;21:538–82. DOI: 10.1128/CMR.00058-07
- Poirel L, Nordmann P. Carbapenem resistance in *Acinetobacter baumannii*: mechanism and epidemiology. *Clin Microbiol Infect*. 2006;12:826–36. DOI: 10.1111/j.1469-0691.2006.01456.x
- Scaife W, Young HK, Paton RH, Amyes GB. Transferable imipenem-resistance in *Acinetobacter* species from a clinical source. *J Antimicrob Chemother*. 1995;36:585–7. DOI: 10.1093/jac/36.3.585
- Poirel L, Figueiredo S, Cattoir V, Carattoli A, Nordmann P. *Acinetobacter radioresistens* as a silent source of carbapenem resistance for *Acinetobacter* spp. *Antimicrob Agents Chemother*. 2008;52:1252–6. DOI: 10.1128/AAC.01304-07
- Stoeva T, Higgins PG, Bojkova K, Seifert H. Clonal spread of carbapenem-resistant OXA-23 positive *Acinetobacter baumannii* in a Bulgarian university hospital. *Clin Microbiol Infect*. 2008;14:723–7. DOI: 10.1111/j.1469-0691.2008.02018.x
- Zhou H, Pi BR, Yang Q, Yu YS, Chen YG, Li LJ, et al. Dissemination of imipenem-resistant *Acinetobacter baumannii* strains carrying the *ISAbal bla*<sub>OXA-23</sub> gene in a Chinese hospital. *J Med Microbiol*. 2007;56:1076–80. DOI: 10.1099/jmm.0.47206-0

8. Carvalho KR, Carvalho-Assef AP, Peirano G, Santos LC, Pereira MJ, Asensi MD. Dissemination of multidrug-resistant *Acinetobacter baumannii* genotypes carrying *bla*<sub>OXA-23</sub> collected from hospitals in Rio de Janeiro, Brazil. *Int J Antimicrob Agents*. 2009;34:25–8. DOI: 10.1016/j.ijantimicag.2008.12.009
9. Calhoun JH, Murray CK, Manring MM. Multidrug-resistant organisms in military wounds from Iraq in Afghanistan. *Clin Orthop Relat Res*. 2008;466:1356–62. DOI: 10.1007/s11999-008-0212-9
10. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem OXA-23 in a tertiary care hospital of Papeete, French Polynesia. *J Clin Microbiol*. 2005;43:4826–9. DOI: 10.1128/JCM.43.9.4826-4829.2005
11. Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. Genetics and expression of the carbapenems-hydrolysing oxacillinase gene *bla*<sub>OXA-23</sub> in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2007;51:1530–3. DOI: 10.1128/AAC.01132-06
12. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, et al. Genetic basis of multidrug resistance in *Acinetobacter baumannii* clinical isolates at a tertiary medical center in Pennsylvania. *Antimicrob Agents Chemother*. 2008;52:3837–43. DOI: 10.1128/AAC.00570-08
13. Mugnier PD, Poirel L, Nordmann P. Functional analysis of insertion sequence *ISAbal*, responsible for genomic plasticity of *Acinetobacter baumannii*. *J Bacteriol*. 2009;191:2414–8. DOI: 10.1128/JB.01258-08
14. Mugnier P, Poirel L, Pitout M, Nordmann P. Carbapenem-resistant and OXA-23 producing *Acinetobacter baumannii* isolates in the United Arab Emirates. *Clin Microbiol Infect*. 2008;14:879–82. DOI: 10.1111/j.1469-0691.2008.02056.x
15. Mugnier PD, Bindayna KM, Poirel L, Nordmann P. Diversity of plasmid-mediated carbapenem-hydrolysing oxacillinases among carbapenem-resistant *Acinetobacter baumannii* isolates from Kingdom of Bahrain. *J Antimicrob Chemother*. 2009;63:1071–3. DOI: 10.1093/jac/dkp052
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. M100–S18. Wayne (PA): The Institute; 2008.
17. Dortet L, Legrand P, Soussy CJ, Cattoir V. Bacterial identification, clinical significance, and antimicrobial susceptibilities of *Acinetobacter ursingii* and *Acinetobacter schindleri*, two frequently misidentified opportunistic pathogens. *J Clin Microbiol*. 2006;44:4471–8. DOI: 10.1128/JCM.01535-06
18. Turton JF, Gabriel SN, Valderrey C, Kaufmann ME, Pitt TL. Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of *Acinetobacter baumannii*. *Clin Microbiol Infect*. 2007;13:807–25. DOI: 10.1111/j.1469-0691.2007.01759.x
19. Bartual SG, Seifert H, Hippler C, Luzon MA, Wisplinghoff H, Rodriguez-Valera F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of *Acinetobacter baumannii*. *J Clin Microbiol*. 2005;43:4382–90. DOI: 10.1128/JCM.43.9.4382-4390.2005
20. Nemeč A, Krizova L, Maixnerova M, Diancourt L, Van der Reijden TJK, Brisse S, et al. Emergence of carbapenem resistance in *Acinetobacter baumannii* in the Czech Republic is associated with the spread of multidrug resistant strains of European clone II. *J Antimicrob Chemother*. 2008;62:484–9. DOI: 10.1093/jac/dkn205
21. Liu SL, Hessel A, Sanderson KE. Genomic mapping with *I-CeuI*, an intron-encoded endonuclease specific for genes for ribosomal RNA, in *Salmonella* spp., *Escherichia coli*, and other bacteria. *Proc Natl Acad Sci U S A*. 1993;90:6874–8. DOI: 10.1073/pnas.90.14.6874
22. Poirel L, Guibert M, Bellais S, Naas T, Nordmann P. Integron- and carbapenemase-mediated reduced susceptibility to amoxicillin-clavulanic acid in isolates of multidrug-resistant *Salmonella enterica* serotype typhimurium DT104 from French patients. *Antimicrob Agents Chemother*. 1999;43:1098–104.
23. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol*. 1995;33:2233–9.
24. Bogaerts P, Cuzon G, Naas T, Bauraing C, Deplano A, Lisssoir B, et al. Carbapenem-resistant *Acinetobacter baumannii* isolates expressing the *bla*<sub>OXA-23</sub> gene associated with *ISAbal4* in Belgium. *Antimicrob Agents Chemother*. 2008;52:4205–6. DOI: 10.1128/AAC.01121-08
25. Park YK, Choi JY, Jung SI, Park KH, Lee H, Jung DS, et al. Two distinct clones of carbapenem-resistant *Acinetobacter baumannii* isolates from Korean hospitals. *Diagn Microbiol Infect Dis*. 2009;64:389–95. DOI: 10.1016/j.diagmicrobio.2009.03.029

Address for correspondence: Patrice Nordmann, Service de Bactériologie-Virologie, Hôpital de Bicêtre, 78 Rue du Général Leclerc, 94275 Le Kremlin-Bicêtre, France; email: nordmann.patrice@bct.ap-hop-paris.fr

Get the content you want delivered to your inbox.

Sign up to receive emailed announcements when new podcasts or articles on topics you select are posted on our website.

[www.cdc.gov/ncidod/eid/subscrib.htm](http://www.cdc.gov/ncidod/eid/subscrib.htm)

Table of contents  
Podcasts  
Ahead of Print  
CME  
Specialized topics

